Hofseth BioCare Management

Management criteria checks 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Key information

Jon Odegard

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	1.7yrs
CEO ownership	n/a
Management average tenure	2.9yrs
Board average tenure	2.3yrs

Recent management updates

Recent updates

Hofseth BioCare (OB:HBC) Shareholders Have Enjoyed A Whopping 339% Share Price Gain

Nov 20

CEO Compensation Analysis

How has Jon Odegard's remuneration changed compared to Hofseth BioCare's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-kr107m
Sep 30 2023	n/a	n/a	-kr93m
Jun 30 2023	n/a	n/a	-kr105m
Mar 31 2023	n/a	n/a	-kr140m
Dec 31 2022	n/a	n/a	-kr137m
Sep 30 2022	n/a	n/a	-kr136m
Jun 30 2022	n/a	n/a	-kr139m
Mar 31 2022	n/a	n/a	-kr135m
Dec 31 2021	n/a	n/a	-kr126m
Sep 30 2021	n/a	n/a	-kr120m
Jun 30 2021	n/a	n/a	-kr115m
Mar 31 2021	n/a	n/a	-kr111m
Dec 31 2020	kr2m	kr695k	-kr102m
Sep 30 2020	n/a	n/a	-kr104m
Jun 30 2020	n/a	n/a	-kr90m
Mar 31 2020	n/a	n/a	-kr86m
Dec 31 2019	kr2m	kr660k	-kr89m
Sep 30 2019	n/a	n/a	-kr79m
Jun 30 2019	n/a	n/a	-kr81m
Mar 31 2019	n/a	n/a	-kr83m
Dec 31 2018	kr2m	kr702k	-kr85m
Sep 30 2018	n/a	n/a	-kr74m
Jun 30 2018	n/a	n/a	-kr66m
Mar 31 2018	n/a	n/a	-kr66m
Dec 31 2017	kr2m	kr2m	-kr16m

Vergütung im Vergleich zum Markt: Unzureichende Daten, um festzustellen, ob die Gesamtvergütung von Jon im Vergleich zu Unternehmen ähnlicher Größe auf dem Markt Norwegian angemessen ist.

Entschädigung vs. Einkommen: JonDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

CEO

Jon Odegard

1.7yrs

Tenure

kr1,701,000

Compensation

Mr. Jon Olav Odegard had been Chief Financial Officer of Hofseth BioCare ASA since August 29, 2016 until 2022 and serves as its Chief Executive Officer since August 1, 2022 and was its Chief Executive Offi...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jon Odegard	Chief Executive Officer	1.7yrs	kr1.70m	no data
Bomi Framroze	Chief Scientific Officer	14.3yrs	kr21.73m	1.32% NOK 10.8m
James Berger	Chief Commercial Officer	3.2yrs	kr7.81m	no data
Angelika Florvaag	Chief Quality Officer	3.2yrs	kr822.00k	no data
Christel Kanli	CFO & COO	1.1yrs	no data	0.019% NOK 153.2k
Crawford Currie	Head of Medical R&D and Director	no data	no data	0.19% NOK 1.6m
Tanja Schaffer	EVP of Global Ingredients Division & CEO of HBC Switzerland GmbH	2.6yrs	no data	no data

2.9yrs

Average Tenure

Erfahrenes Management: HBCDas Führungsteam des Unternehmens gilt als erfahren (2.5 Jahre durchschnittliche Betriebszugehörigkeit).

Board Members

Name	Position	Tenure	Compensation	Ownership
Crawford Currie	Head of Medical R&D and Director	2.3yrs	no data	0.19% NOK 1.6m
Roger Hofseth	Director	1.7yrs	no data	17.59% NOK 143.9m
Amy Novogratz	Independent Director	2.3yrs	no data	no data
Christoph Baldegger	Independent Director	9.3yrs	kr96.00k	0.20% NOK 1.7m
Torill Eliassen	Independent Director	8.8yrs	kr116.00k	0.051% NOK 414.0k

2.3yrs

Average Tenure

49yo

Average Age

Erfahrener Vorstand: HBCDie Vorstandsmitglieder gelten nicht als erfahren ( 2.5 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

Hofseth BioCare Management

Management criteria checks 2/4

Key information

Recent management updates

Hofseth BioCare ASA Announces Board Changes

CFO & COO recently bought kr200k worth of stock

Chief Scientific Officer recently bought kr538k worth of stock

Independent Director recently bought kr272k worth of stock

Hofseth BioCare ASA Announces Executive Changes

Chief Executive Officer recently bought kr170k worth of stock

Recent updates

New minor risk - Share price stability

Hofseth BioCare ASA Announces Board Changes

New major risk - Financial position

Full year 2023 earnings released: kr0.27 loss per share (vs kr0.37 loss in FY 2022)

Hofseth BioCare ASA to Report Q4, 2024 Results on Feb 14, 2025

Third quarter 2023 earnings released: kr0.06 loss per share (vs kr0.09 loss in 3Q 2022)

New minor risk - Market cap size

Second quarter 2023 earnings released: EPS: kr0.015 (vs kr0.079 loss in 2Q 2022)

CFO & COO recently bought kr200k worth of stock

New minor risk - Market cap size

Hofseth Biocare ASA Announces the Online Publication of Its Abstract

First quarter 2023 earnings released: kr0.10 loss per share (vs kr0.10 loss in 1Q 2022)

Here's Why Hofseth BioCare (OB:HBC) Can Afford Some Debt

Chief Scientific Officer recently bought kr538k worth of stock

Independent Director recently bought kr272k worth of stock

Full year 2022 earnings released: kr0.37 loss per share (vs kr0.35 loss in FY 2021)

We Think Hofseth BioCare (OB:HBC) Has A Fair Chunk Of Debt

Hofseth BioCare ASA to Report Fiscal Year 2022 Results on Mar 31, 2023

Third quarter 2022 earnings released: kr0.09 loss per share (vs kr0.11 loss in 3Q 2021)

Third quarter 2022 earnings released: kr0.09 loss per share (vs kr0.11 loss in 3Q 2021)

Hofseth BioCare ASA's Progo Bioactive Peptides Now Is A "New Dietary Ingredient" for the US FDA

Second quarter 2022 earnings released: kr0.08 loss per share (vs kr0.069 loss in 2Q 2021)

Hofseth BioCare ASA Announces Executive Changes

Chief Executive Officer recently bought kr170k worth of stock

First quarter 2022 earnings released: kr0.10 loss per share (vs kr0.075 loss in 1Q 2021)

Health Check: How Prudently Does Hofseth BioCare (OB:HBC) Use Debt?

Full year 2021 earnings released: kr0.35 loss per share (vs kr0.31 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Chief Executive Officer recently bought kr367k worth of stock

Hofseth Biocare ASA Successfully Receive New Dietary Ingredient (NDI) Status from the US FDA

Third quarter 2021 earnings released: kr0.11 loss per share (vs kr0.10 loss in 3Q 2020)

Hofseth BioCare (OB:HBC) Is Carrying A Fair Bit Of Debt

Chief Commercial Officer recently bought kr200k worth of stock

Chief Executive Officer recently bought kr361k worth of stock

Second quarter 2021 earnings released: kr0.07 loss per share (vs kr0.062 loss in 2Q 2020)

Hofseth BioCare ASA Provides Earnings Guidance for the Second Half of 2021 and Next Year 2022

Independent Director recently bought kr385k worth of stock

First quarter 2021 earnings released: kr0.08 loss per share (vs kr0.055 loss in 1Q 2020)

Full year 2020 earnings released: kr0.31 loss per share (vs kr0.29 loss in FY 2019)

Is Hofseth BioCare (OB:HBC) Using Debt Sensibly?

Full year 2020 earnings released: kr0.31 loss per share (vs kr0.29 loss in FY 2019)

How Much Of Hofseth BioCare ASA (OB:HBC) Do Insiders Own?

Chief Executive Officer recently bought kr505k worth of stock

Chief Executive Officer recently bought kr505k worth of stock

Chief Executive Officer recently bought kr505k worth of stock

New 90-day high: kr9.80

Are Insiders Buying Hofseth BioCare ASA (OB:HBC) Stock?

Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 39.999995 million.

Hofseth Biocare ASA and Tenet Partners Initiate A Long-Term Collaboration to Build A Global Brand and Launch HBC Own Branded Consumer Health Products

Hofseth BioCare ASA and DKSH Announces A Pan-Asian Exclusive Collaboration for Distribution of HBC Branded Products Including Across China, India, Japan & Korea

Hofseth Biocare Asa Signs Exclusive Distribution Agreement with Leading Speciality Chemicals and Ingredients Distributor IMCD

Hofseth Biocare ASA Hires Andy Gill as VP from January 2021

Hofseth BioCare ASA, Annual General Meeting, Apr 23, 2021

Hofseth BioCare (OB:HBC) Shareholders Have Enjoyed A Whopping 339% Share Price Gain

Hofseth Biocare ASA Approves Appointment of Christoph Baldegger as New Member of the Audit Committee

Third quarter earnings released

New 90-day low: kr7.98

HBC Receives Approval from Health Canada for Qualified Health Claims Focused on Maintaining Healthy Levels of Ferritin and Hemoglobin and the Blood Components Required for Oxygen Transport

Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 200 million.

Hofseth Biocare ASA's Progo’s Bioactive Peptides to Support Healthy Iron Levels to Be Launched in the US

Hofseth BioCare ASA Announces the First Part of its Accelerated Phase 2 Trial of Cardio™ Soft Gels for the Treatment of Patients with COVID-19

New 90-day low - kr8.16

First half earnings released

Hofseth BioCare ASA (OB:HBC) acquired a 34% stake in Atlantic Delights Ltd. for $0.7 million.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team